Chi-Med/AstraZeneca Drug Shows Efficacy Against Lung Cancer
Chi-Med (Hutchison China MediTech) and AstraZeneca presented positive safety and efficacy data of their partnered drug, the c-MET inhibitor savolitinib. Savolitinib was administered together with one of two AstraZeneca drugs -- Tagrisso® (osimertinib) or Iressa® (gefitinib) -- in two Phase Ib/II proof-of-concept trials in patients with non-small cell lung cancer. The patients had failed an earlier first-line treatment with an EGFR inhibitor. The most advanced savolitinib study is a recently started Phase III trial as a first-line treatment in patients with papillary renal cell carcinoma. More details....
Stock Symbols: (AIM/NSDQ: HCM) (NYSE: AZN)
Share this with colleagues:
Original Article: Chi-Med/AstraZeneca Drug Shows Efficacy Against Lung Cancer
